Drug maker pursuing novel approach to establishing that contract pharmacies are improperly taking ‘title’ to 340B-discounted drugs, leading to diversion, which is prohibited by law.

CDER holds steady with a median time to approval of 11 months, while CBER posts 10.5 month median review time for its largest novel approvals class.

Some drugs recorded significant increases in Medicare gross spending between the periods covered by publicly available data and what CMS had access to internally, which contributed to their unexpected presence on the list.

As well as making waves in the treatment of obesity, debate has been stirring around the ability of GLP-1s to combat drug addiction, manage heart disease and also protect individuals against Parkinson’s disease. How can medtechs get in on the potential gains?